Guidelines for the treatment of psoriasis with biologic agents in China (2021)

Keyword(s):  
2005 ◽  
Vol 35 (7) ◽  
pp. 33
Author(s):  
Mitchel L. Zoler ◽  
Timothy F. Kirn
Keyword(s):  

2020 ◽  
Vol 47 (4) ◽  
pp. 733-742
Author(s):  
Ibrahim Hammad ◽  
T. Flint Porter
Keyword(s):  

2021 ◽  
Vol 13 ◽  
pp. 1759720X2110026
Author(s):  
Chinar R. Parikh ◽  
Jaya K. Ponnampalam ◽  
George Seligmann ◽  
Leda Coelewij ◽  
Ines Pineda-Torra ◽  
...  

The treatment of inflammatory arthritis has been revolutionised by the introduction of biologic treatments. Many biologic agents are currently licensed for use in both paediatric and adult patients with inflammatory arthritis and contribute to improved disease outcomes compared with the pre-biologic era. However, immunogenicity to biologic agents, characterised by an immune reaction leading to the production of anti-drug antibodies (ADAs), can negatively impact the therapeutic efficacy of biologic drugs and induce side effects to treatment. This review explores for the first time the impact of immunogenicity against all licensed biologic treatments currently used in inflammatory arthritis across age, and will examine any significant differences between ADA prevalence, titres and timing of development, as well as ADA impact on therapeutic drug levels, clinical efficacy and side effects between paediatric and adult patients. In addition, we will investigate factors associated with differences in immunogenicity across biologic agents used in inflammatory arthritis, and their potential therapeutic implications.


Sign in / Sign up

Export Citation Format

Share Document